Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is an American clinical-stage biopharmaceutical enterprise developing small molecule and antibody immuno-oncology therapies targeting T-cell pathways. The company advances clinical pipeline candidates including soquelitinib (ITK inhibitor) for T-cell lymphoma, peripheral T-cell lymphoma, and autoimmune diseases, alongside ciforadenant (A2A receptor antagonist) for solid tumors. Principal revenue is driven through research milestone payments, strategic development partnerships, and capital raises prior to commercial market authorization. Core end markets serve medical oncology centers, hematology cancer institutes, immunology research clinics, and prescription patients globally. Corvus Pharmaceuticals holds an innovative position in the biopharmaceutical sector as a pioneer of ITK-selective small molecule inhibitors for T-cell malignancies and immunology. The corporation is headquartered in Burlingame, California, and its common stock trades on the Nasdaq Global Market.
3 of the funds FundTelligence covers report a position in Corvus Pharmaceuticals.
- Legal name
- Corvus Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Corvus Pharmaceuticals
- SEB Läkemedelsfond — SEB · 0.19 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)